Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.


Journal

Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941

Informations de publication

Date de publication:
05 2019
Historique:
entrez: 21 5 2019
pubmed: 21 5 2019
medline: 10 3 2020
Statut: ppublish

Résumé

Background Identifying the mechanistic pathways potentially associated with incident heart failure (HF) may provide a basis for novel preventive strategies. Methods and Results To identify proteomic biomarkers and the potential underlying mechanistic pathways that may be associated with incident HF defined as the first hospitalization for HF, a nested-matched case-control design was used with cases (incident HF) and controls (without HF) selected from 3 cohorts (>20 000 individuals). Controls were matched on cohort, follow-up time, age, and sex. Two independent sample sets (a discovery set with 286 cases and 591 controls and a replication set with 276 cases and 280 controls) were used to discover and replicate the findings. Two hundred fifty-two circulating proteins in the plasma were studied. Adjusting for the matching variables age, sex, and follow-up time (and correcting for multiplicity of tests), 89 proteins were found to be associated with incident HF in the discovery phase, of which 38 were also associated with incident HF in the replication phase. These 38 proteins pointed to 4 main network clusters underlying incident HF: (1) inflammation and apoptosis, indicated by the expression of the TNF (tumor necrosis factor)-family members; (2) extracellular matrix remodeling, angiogenesis and growth, indicated by the expression of proteins associated with collagen metabolism, endothelial function, and vascular homeostasis; (3) blood pressure regulation, indicated by the expression of natriuretic peptides and proteins related to the renin-angiotensin-aldosterone system; and (4) metabolism, associated with cholesterol and atherosclerosis. Conclusions Clusters of biomarkers associated with mechanistic pathways leading to HF were identified linking inflammation, apoptosis, vascular function, matrix remodeling, blood pressure control, and metabolism. These findings provide important insight on the pathophysiological mechanisms leading to HF. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02556450.

Identifiants

pubmed: 31104495
doi: 10.1161/CIRCHEARTFAILURE.118.005897
pmc: PMC8361846
mid: NIHMS1725998
doi:

Substances chimiques

Biomarkers 0
Proteome 0

Banques de données

ClinicalTrials.gov
['NCT02556450']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e005897

Subventions

Organisme : Intramural NIH HHS
ID : Z01 HL006001
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 HL999999
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA HL006001
Pays : United States

Références

J Biol Chem. 2007 Sep 21;282(38):28175-88
pubmed: 17635925
Stat Methods Med Res. 2018 Jun;27(6):1634-1649
pubmed: 27647809
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2331-2336
pubmed: 28193895
Cardiovasc Res. 2004 Sep 1;63(4):603-10
pubmed: 15306215
Mol Cell Endocrinol. 2007 Jul 15;273(1-2):59-67
pubmed: 17587490
J Biol Chem. 2006 Jun 2;281(22):15345-51
pubmed: 16554301
Circ Res. 2011 Jul 22;109(3):272-80
pubmed: 21636802
Cytokine. 2016 Apr;80:7-12
pubmed: 26916171
Sci Rep. 2017 Jan 23;7:40994
pubmed: 28112232
JACC Heart Fail. 2016 Nov;4(11):860-869
pubmed: 27744089
Eur Heart J. 2014 Jul 14;35(27):1782-91
pubmed: 24864079
Oncotarget. 2016 Oct 4;7(40):64649-64664
pubmed: 27579618
J Am Heart Assoc. 2017 May 2;6(5):
pubmed: 28465299
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
JAMA. 2013 Jul 3;310(1):66-74
pubmed: 23821090
Am J Epidemiol. 1992 May 1;135(9):1042-50
pubmed: 1595690
Eur J Heart Fail. 2012 Jul;14(7):718-29
pubmed: 22562498
Eur J Prev Cardiol. 2017 Oct;24(15):1576-1583
pubmed: 28762762
J Am Coll Cardiol. 2014 Apr 29;63(16):1593-603
pubmed: 24530674
Am J Cardiol. 1999 Nov 15;84(10):1192-7
pubmed: 10569329
J Biomed Res. 2014 Sep;28(5):349-59
pubmed: 25332706
Atherosclerosis. 2010 Dec;213(2):545-8
pubmed: 20843516
JAMA Cardiol. 2018 Mar 1;3(3):215-224
pubmed: 29322198
Cardiol Clin. 2014 Feb;32(1):21-32, vii
pubmed: 24286576
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Vascul Pharmacol. 2016 Feb;77:60-8
pubmed: 26304698
Heart Fail Clin. 2018 Jan;14(1):49-55
pubmed: 29153200
Clin Chem. 2017 Jan;63(1):140-151
pubmed: 28062617
Matrix Biol. 2017 Jan;57-58:285-298
pubmed: 27613501
Front Immunol. 2015 Apr 14;6:158
pubmed: 25926831
Eur J Heart Fail. 2011 May;13(5):528-36
pubmed: 21454299
Nucleic Acids Res. 2011 Aug;39(15):e102
pubmed: 21646338
Life Sci. 2014 Nov 18;118(1):1-6
pubmed: 25265596
Am J Epidemiol. 1992 May 1;135(9):1019-28
pubmed: 1595688
Heart. 2000 May;83(5):596-602
pubmed: 10768918
Eur J Heart Fail. 2014 Apr;16(4):377-83
pubmed: 24464777
Circ Heart Fail. 2015 May;8(3):438-47
pubmed: 25737496
Stat Appl Genet Mol Biol. 2007;6:Article27
pubmed: 18052910
Nat Protoc. 2016 Oct;11(10):1889-907
pubmed: 27606777
Circulation. 2012 Sep 25;126(13):1596-604
pubmed: 22907935
Bioinformatics. 2010 Nov 1;26(21):2737-43
pubmed: 20798171
Lancet. 2001 Aug 11;358(9280):432-4
pubmed: 11513900
Eur J Intern Med. 2017 Oct;44:31-38
pubmed: 28579310
Cardiovasc Diabetol. 2015 May 13;14:52
pubmed: 25964115
Front Immunol. 2014 Jan 20;5:3
pubmed: 24478772
Am Heart J. 2003 Oct;146(4):581-90
pubmed: 14564310
Mol Cell. 1999 Oct;4(4):563-71
pubmed: 10549288
Lancet. 2018 Feb 10;391(10120):518-519
pubmed: 29174291
J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090
pubmed: 30165978
J Gerontol A Biol Sci Med Sci. 2013 May;68(5):617-23
pubmed: 23109678
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
Am J Epidemiol. 1992 May 1;135(9):1029-41
pubmed: 1595689
J Heart Lung Transplant. 2006 Feb;25(2):174-80
pubmed: 16446217
Acta Crystallogr F Struct Biol Commun. 2015 Oct;71(Pt 10):1273-81
pubmed: 26457518
Mol Biol Rep. 2012 Aug;39(8):8231-41
pubmed: 22555979
Angiology. 2018 May;69(5):424-430
pubmed: 28847153
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292
Eur Heart J. 1998 Dec;19 Suppl P:P9-16
pubmed: 9886707
PLoS One. 2014 Apr 17;9(4):e94106
pubmed: 24743304
Heart. 1996 Nov;76(3 Suppl 3):36-44
pubmed: 8983665
Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1723-31
pubmed: 25953645
Eur J Med Chem. 2017 Sep 29;138:854-873
pubmed: 28738306
Eur J Heart Fail. 2018 Jan;20(1):55-62
pubmed: 28967680
Am J Physiol Heart Circ Physiol. 2016 Nov 1;311(5):H1189-H1201
pubmed: 27591224
JAMA Cardiol. 2018 Apr 1;3(4):318-325
pubmed: 29516098

Auteurs

João Pedro Ferreira (JP)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Portugal (J.P.F.).

Job Verdonschot (J)

Department of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, the Netherlands (J.V., M.H., S.H.).
Department of Clinical Genetics, Maastricht University Medical Center, the Netherlands (J.V., P.W.).

Timothy Collier (T)

London School of Hygiene and Tropical Medicine, United Kingdom (T.C.).

Ping Wang (P)

Department of Clinical Genetics, Maastricht University Medical Center, the Netherlands (J.V., P.W.).

Anne Pizard (A)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).
Inserm 1024, Institut de Biologie de l'École Normale Supérieure (IBENS), PSL University of Paris, France (A.P.).

Christian Bär (C)

Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Germany (C.B., T.T.).

Alessandro Boccanelli (A)

Casa di Cura Quisisana, Rome, Italy (A.B.).

Javed Butler (J)

TATAA Biocenter AB, Gothenburg, Sweden (J.B.).
Department of Medicine, University of Mississippi School of Medicine, Jackson (J.B.).
Excellence Cluster REBIRTH, Hannover Medical School, Germany (J.B.).

Andrew Clark (A)

Hull York Medical School, Castle Hill Hospital, Cottingham, United Kingdom (A.C.).

John G Cleland (JG)

Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, Glasgow, United Kingdom (J.G.C.).
National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, University of Glasgow, London, United Kingdom (J.G.C.).

Christian Delles (C)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, United Kingdom (C.D.).

Javier Diez (J)

Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain (J.D., A.G.).
CIBERCV, Carlos III Institute of Health, Madrid, Spain (J.D., A.G.).
Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain (J.D., A.G.).
Departments of Nephrology, and Cardiology and Cardiac Surgery, University of Navarra Clinic, Pamplona, Spain (J.D.).

Nicolas Girerd (N)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).

Arantxa González (A)

Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain (J.D., A.G.).
CIBERCV, Carlos III Institute of Health, Madrid, Spain (J.D., A.G.).
Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain (J.D., A.G.).

Mark Hazebroek (M)

Department of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, the Netherlands (J.V., M.H., S.H.).

Anne-Cécile Huby (AC)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).

Wouter Jukema (W)

Department of Cardiology, Leiden University Medical Center, the Netherlands (W.J.).

Roberto Latini (R)

IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy (R.L.).

Joost Leenders (J)

ACS Biomarker BV, Amsterdam, the Netherlands (J.L.).

Daniel Levy (D)

National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, MA (D.L.).
Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD (D.L.). UMRS 942, University Paris Diderot.

Alexandre Mebazaa (A)

APHP, University Hospitals Saint Louis Lariboisière, France (A.M., N.V.).

Harald Mischak (H)

Mosaiquesdiagnostics, Hannover, Germany (H.M.).

Florence Pinet (F)

Inserm U1167, Institut Pasteur de Lille, Université de Lille, FHU-REMOD-VHF, France (F.P.).

Patrick Rossignol (P)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).

Naveed Sattar (N)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (N.S.).

Peter Sever (P)

International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, England (P.S.).

Jan A Staessen (JA)

Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S., Z.-Y.Z.).
Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, the Netherlands (J.A.S.).

Thomas Thum (T)

Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Germany (C.B., T.T.).
National Heart and Lung Institute, Imperial College London, United Kingdom (T.T.).

Nicolas Vodovar (N)

APHP, University Hospitals Saint Louis Lariboisière, France (A.M., N.V.).

Zhen-Yu Zhang (ZY)

Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S., Z.-Y.Z.).

Stephane Heymans (S)

Department of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, the Netherlands (J.V., M.H., S.H.).
Department of Cardiovascular Research, University of Leuven, Belgium (S.H.). Netherlands Heart Institute (ICIN), Utrecht, the Netherlands (S.H.).

Faiez Zannad (F)

Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., A.P., N.G., A.-C.H., P.R., F.Z.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH